264 related articles for article (PubMed ID: 32055900)
21. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
22. Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.
Bilgetekin I; Erturk I; Basal FB; Karacin C; Karadurmus N; Oksuzoglu B; Demirci U
Int Urol Nephrol; 2021 Feb; 53(2):301-307. PubMed ID: 32869173
[TBL] [Abstract][Full Text] [Related]
23. Overcorrection and undercorrection with fixed dosing of bolus hypertonic saline for symptomatic hyponatremia.
Pelouto A; Refardt JC; Christ-Crain M; Zandbergen AAM; Hoorn EJ
Eur J Endocrinol; 2023 Mar; 188(3):322-330. PubMed ID: 36881992
[TBL] [Abstract][Full Text] [Related]
24. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
Jia JD; Xie W; Ding HG; Mao H; Guo H; Li Y; Wang X; Wang JF; Lu W; Li CZ; Mao Y; Wang GQ; Gao YQ; Wang B; Zhang Q; Ge Y; Wong VW
Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801
[TBL] [Abstract][Full Text] [Related]
25. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
[TBL] [Abstract][Full Text] [Related]
26. Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery.
Kleindienst A; Georgiev S; Schlaffer SM; Buchfelder M
J Endocr Soc; 2020 Jul; 4(7):bvaa068. PubMed ID: 32666012
[TBL] [Abstract][Full Text] [Related]
27. Long-term low-dose tolvaptan efficacy and safety in SIADH.
Bondanelli M; Aliberti L; Gagliardi I; Ambrosio MR; Zatelli MC
Endocrine; 2023 Nov; 82(2):390-398. PubMed ID: 37507553
[TBL] [Abstract][Full Text] [Related]
28. [Effectiveness and adequacy of tolvaptan prescription in hospitalized patients].
Edo Solsona MD; Ruiz Ramos J; Montero Hernández M; Font Noguera I; Poveda Andrés JL
Farm Hosp; 2013; 37(3):178-81. PubMed ID: 23789795
[TBL] [Abstract][Full Text] [Related]
29. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
[TBL] [Abstract][Full Text] [Related]
30. Tolvaptan and urea in paediatric hyponatraemia.
Veligratli F; Alexandrou D; Shah S; Amin R; Dattani M; Gan HW; Famuboni A; Lopez-Garcia C; Trompeter R; Bockenhauer D
Pediatr Nephrol; 2024 Jan; 39(1):177-183. PubMed ID: 37466863
[TBL] [Abstract][Full Text] [Related]
31. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
32. The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases.
Ren P; Yang Q
Transl Cancer Res; 2021 Mar; 10(3):1229-1237. PubMed ID: 35116450
[TBL] [Abstract][Full Text] [Related]
33. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
[TBL] [Abstract][Full Text] [Related]
34. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
Humayun MA; Cranston IC
BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
[TBL] [Abstract][Full Text] [Related]
35. Derivation and Validation of a Novel Risk Score to Predict Overcorrection of Severe Hyponatremia: The Severe Hyponatremia Overcorrection Risk (SHOR) Score.
Woodfine JD; Sood MM; MacMillan TE; Cavalcanti RB; van Walraven C
Clin J Am Soc Nephrol; 2019 Jul; 14(7):975-982. PubMed ID: 31189541
[TBL] [Abstract][Full Text] [Related]
36. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
Rajendran R; Grossman AB; Kar P
Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335
[TBL] [Abstract][Full Text] [Related]
37. Tolvaptan increases serum sodium in pediatric patients with heart failure.
Regen RB; Gonzalez A; Zawodniak K; Leonard D; Quigley R; Barnes AP; Koch JD
Pediatr Cardiol; 2013 Aug; 34(6):1463-8. PubMed ID: 23463133
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
39. [Hyponatremia : The water-intolerant patient].
Hensen J
Med Klin Intensivmed Notfmed; 2012 Sep; 107(6):440-7. PubMed ID: 22911166
[TBL] [Abstract][Full Text] [Related]
40. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
Verbalis JG; Greenberg A; Burst V; Haymann JP; Johannsson G; Peri A; Poch E; Chiodo JA; Dave J
Am J Med; 2016 May; 129(5):537.e9-537.e23. PubMed ID: 26584969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
